GlassScriptPhysician profile
Douglas M Mayo
NPI 1942674254
$2,231.20
in general payments reported to CMS, 2019-2025
26 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.67 · 2022: $140 · 2023: $472 · 2024: $498 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.96 | 2022-2025 | |
| Novo Nordisk INC | $256.42 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $153.21 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $143.10 | 2024-2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $127.34 | 2025 | Fanapt |
| Pfizer INC. | $119.34 | 2021-2025 | |
| Cranial Technologies, INC | $70.02 | 2024-2025 | Doc Band |
| Amgen INC. | $60.55 | 2024-2025 | Repatha, Otezla, Prolia |
| Exact Sciences Corporation | $56.40 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $48.93 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.38 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $43.47 | 2024-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $42.96 | 2022-2025 | Varivax, M-M-R II, Capvaxive |
| Astellas Pharma US INC | $42.47 | 2022-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $42.15 | 2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $40.94 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Mylan Specialty L.P. | $31.55 | 2022-2024 | Yupelri |
| Nestle Healthcare Nutrition INC. | $31.08 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.83 | 2024-2025 | Zoryve |
| Lundbeck LLC | $21.96 | 2025 | Rexulti |
| Nevro Corp. | $19.91 | 2024 | Senza |
| Alkermes, INC. | $19.61 | 2025 | Lybalvi |
| Sumitomo Pharma America, INC. | $18.54 | 2023-2025 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $17.00 | 2025 | Azmiro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.08 | 2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $9.00 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.